The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Abstract
Summary: Although plasminogen activator inhibitor 1 (PAI-1) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration. PAI-1 also differs from other serine protease inhibitors (serpins) in that it is a trace protein in plasma, it has a short half-life in vivo, its synthesis is highly regulated, and it binds to the adhesive glycoprotein vitronectin (VN) with high affinity and specificity. These unique and diverse properties of PAI-1 probably account for the many observations in the literature that correlate abnormalities in PAI-1 gene expression with a variety of pathological conditions. In this review, we discuss the discovery, origin, properties and regulation of PAI-1, and then speculate about its potential role in vascular disease, fibrosis, obesity and the metabolic syndrome, and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“, integrins and uPAR) are essential for optimal motility (54).”
BackgroundThe Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
The plasminogen activator/plasmin system.
Vassalli, J. D., Sappino, A. P., & Belin, D. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115405 · Cited by 1,164
Plasminogen activator inhibitors
Sprengers, E., & Kluft, C. (1987) · Blood · doi:10.1182/blood.v69.2.381.381 · Cited by 1,009
The plasminogen activation system in tumor growth, invasion, and metastasis
Andreasen, P. A., Egelund, R., & Petersen, H. H. (2000) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050497 · Cited by 943
Burke, A. P., Kolodgie, F. D., Farb, A., Weber, D. K., Malcom, G. T., Smialek, J., & Virmani, R. (2001) · Circulation · doi:10.1161/01.cir.103.7.934 · Cited by 919
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 806
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
Regulation of Integrin Function by the Urokinase Receptor
Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., & Chapman, H. A. (1996) · Science · doi:10.1126/science.273.5281.1551 · Cited by 727
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677
The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
Stefansson, S., & Lawrence, D. A. (1996) · Nature · doi:10.1038/383441a0 · Cited by 674
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
Tsirka, S. E., Gualandris, A., Amaral, D. G., & Strickland, S. (1995) · Nature · doi:10.1038/377340a0 · Cited by 663
Wang, Y. F., Tsirka, S. E., Strickland, S., Stieg, P. E., Soriano, S. G., & Lipton, S. A. (1998) · Nature Medicine · doi:10.1038/nm0298-228 · Cited by 630
Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 615
Identification of the urokinase receptor as an adhesion receptor for vitronectin.
Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., & Chapman, H. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31646-6 · Cited by 581
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558
Structural basis of latency in plasminogen activator inhibitor-1
Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D., & Goldsmith, E. J. (1992) · Nature · doi:10.1038/355270a0 · Cited by 553
Hekman, C. M., & Loskutoff, D. J. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39071-3 · Cited by 547
Self-citationSchleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A., & Loskutoff, D. J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60636-2 · Cited by 546
Self-citationIncreased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.
Schneiderman, J., Sawdey, M. S., Keeton, M. R., Bordin, G. M., Bernstein, E. F., Dilley, R. B., & Loskutoff, D. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6998 · Cited by 543
Self-citationDeclerck, P. J., De Mol, M., Alessi, M. C., Baudner, S., Pâques, E. P., Preissner, K. T., Müller-Berghaus, G., & Collen, D. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37610-0 · Cited by 485
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
van Mourik, J. A., Lawrence, D. A., & Loskutoff, D. J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42691-3 · Cited by 450
Self-citationDeng, G., Curriden, S. A., Wang, S., Rosenberg, S., & Loskutoff, D. J. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.6.1563 · Cited by 448
Self-citationAndreotti, F., Davies, G. J., Hackett, D. R., Khan, M. I., De Bart, A. C. W., Aber, V. R., Maseri, A., & Kluft, C. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90669-8 · Cited by 422
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Gelder, M. E. M., Henzen-Logmans, S. C., et al. (2000) · PubMed · Cited by 419
Expression of transforming growth factor-β isoforms in human glomerular diseases
Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A. (1996) · Kidney International · doi:10.1038/ki.1996.65 · Cited by 418
Felding-Habermann, B., & Cheresh, D. A. (1993) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(93)90036-p · Cited by 413
Sawdey, M. S., & Loskutoff, D. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115440 · Cited by 410
Self-citationPrevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Ma, L.-J., Mao, S.-L., Taylor, K. L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N. J., Swift, L. L., McGuinness, O. P., Wasserman, D. H., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.2.336 · Cited by 397
Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
Angleton, P., Chandler, W. L., & Schmer, G. (1989) · Circulation · doi:10.1161/01.cir.79.1.101 · Cited by 392
Carmeliet, P., Stassen, J. M., Schoonjans, L., Ream, B., van den Oord, J. J., De Mol, M., Mulligan, R. C., & Collen, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116893 · Cited by 388
Ossowski, L., & Aguirre-Ghiso, J. A. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00140-x · Cited by 380
Ny, T., Sawdey, M., Lawrence, D., Millan, J. L., & Loskutoff, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.6776 · Cited by 379
Self-citationPlasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00279.x · Cited by 371 · cited 3×
“significantly reduces plasma PAI-1 levels in obese individuals (113).”
BackgroundInfluentialThe plasminogen activator system: biology and regulation
Irigoyen, J. P., Muñoz-Cánoves, P., Montero, L., Koziczak, M., & Nagamine, Y. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000615 · Cited by 368
cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.
Ginsburg, D., Zeheb, R., Yang, A. Y., Rafferty, U. M., Andreasen, P. A., Nielsen, L., Dano, K., Lebo, R. V., & Gelehrter, T. D. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112761 · Cited by 346
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.
Pannekoek, H., Veerman, H., Lambers, H., Diergaarde, P., Verweij, C. L., van Zonneveld, A. J., & van Mourik, J. A. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04532.x · Cited by 344
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors
Kruithof, E., Tran-Thang, C., Gudinchet, A., Hauert, J., Nicoloso, G., Genton, C., Welti, H., & Bachmann, F. (1987) · Blood · doi:10.1182/blood.v69.2.460.460 · Cited by 338
Biological and clinical aspects of plasminogen activator inhibitor type 2
Kruithof, E., Baker, M., & Bunn, C. (1995) · Blood · doi:10.1182/blood.v86.11.4007.bloodjournal86114007 · Cited by 338
Czekay, R.-P., Aertgeerts, K., Curriden, S. A., & Loskutoff, D. J. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208117 · Cited by 304
Self-citationSamad, F., Yamamoto, K., & Loskutoff, D. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118404 · Cited by 301
Self-citationKluft, C., Verheijen, J. H., Jie, A. F. H., Rijken, D. C., Preston, F. E., Sue-Ling, H. M., Jespersen, J., & Aasen, A. O. (1985) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518509155267 · Cited by 298
Juhan-Vague, I., Roul, C., Alessi, M. C., Ardissone, J. P., Heim, M., & Vague, P. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646598 · Cited by 289
Waltz, D. A., Natkin, L. W., Fujita, R. M., Wei, Y., & Chapman, H. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119521 · Cited by 288
The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
Devy, L., Blacher, S., Grignet-Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0552com · Cited by 280
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction
Oda, T., Jung, Y. O., Kim, H. S., Cai, X., López-Guisa, J. M., Ikeda, Y., & Eddy, A. A. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.030002587.x · Cited by 274
Depressed Bronchoalveolar Urokinase Activity in Patients with Adult Respiratory Distress Syndrome
Bertozzi, P., Astedt, B., Zenzius, L., Lynch, K., LeMaire, F., Zapol, W., & Chapman, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003293221304 · Cited by 268
Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
Erickson, L. A., Fici, G. J., Lund, J. E., Boyle, T. P., Polites, H. G., & Marotti, K. R. (1990) · Nature · doi:10.1038/346074a0 · Cited by 267
The Adipocyte and Hemostatic Balance in Obesity: Studies of PAI-1
Loskutoff, D. J., & Samad, F. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.1 · Cited by 264
Self-citationPlasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis
McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K. K., Westrick, R. J., Ginsburg, D., Brooks, P. C., & Lawrence, D. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105980200 · Cited by 263
Lupu, F., Bergonzelli, G. E., Heim, D. A., Cousin, E., Genton, C. Y., Bachmann, F., & Kruithof, E. K. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.7.1090 · Cited by 257
Fay, W. P., Parker, A. C., Condrey, L. R., & Shapiro, A. D. (1997) · Blood · doi:10.1182/blood.v90.1.204 · Cited by 251
Cytokines in the Pathogenesis of Atherosclerosis
Young, J., Libby, P., & Schönbeck, U. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613256 · Cited by 248
Kjøller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Rønne, E., Goodman, S. L., Preissner, K. T., Ossowski, L., & Andreasen, P. A. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3540 · Cited by 233
Jänicke, F., Schmitt, M., & Graeff, H. (1991) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2007-1002624 · Cited by 227
Lundgren, C. H., Brown, S. L., Nordt, T. K., Sobel, B. E., & Fujii, S. (1996) · Circulation · doi:10.1161/01.cir.93.1.106 · Cited by 224
Chen, Y.-Q., Su, M., Walia, R. R., Hao, Q., Covington, J. W., & Vaughan, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8225 · Cited by 217
Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F., & Danø, K. (1986) · FEBS Letters · doi:10.1016/0014-5793(86)81113-9 · Cited by 209
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
Eitzman, D. T., Westrick, R. J., Nabel, E. G., & Ginsburg, D. (2000) · Blood · doi:10.1182/blood.v95.2.577 · Cited by 203
Degryse, B., Neels, J. G., Czekay, R.-P., Aertgeerts, K., Kamikubo, Y.-I., & Loskutoff, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313004200 · Cited by 201
Self-citationPlasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock
Pralong, G., Calandra, T., Glausef, M.-P., Schellekens, J., Verhoef, J., Bachmann, F., & Kruithof, E. K. O. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646614 · Cited by 199
Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice
Samad, F., & Loskutoff, D. J. (1996) · Molecular Medicine · doi:10.1007/bf03401641 · Cited by 188
Self-citationInduction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
Nordt, T. K., Sawa, H., Fujii, S., & Sobel, B. E. (1995) · Circulation · doi:10.1161/01.cir.91.3.764 · Cited by 185
Schäfer, K., Fujisawa, K., Konstantinides, S., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0750fje · Cited by 174
Self-citationPlasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma
Wiman, B., Almquist, Å., Sigurdardottir, O., & Lindahl, T. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80999-2 · Cited by 173
Eren, M., Painter, C. A., Atkinson, J. B., Declerck, P. J., & Vaughan, D. E. (2002) · Circulation · doi:10.1161/01.cir.0000023186.60090.fb · Cited by 170
Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Stefansson, S., McMahon, G., Petitclerc, E., & Lawrence, D. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454621 · Cited by 169
Konstantinides, S., Schäfer, K., Thinnes, T., & Loskutoff, D. J. (2001) · Circulation · doi:10.1161/01.cir.103.4.576 · Cited by 163
Self-citationYamamoto, K., Takeshita, K., Shimokawa, T., Yi, H., Isobe, K.-I., Loskutoff, D. J., & Saito, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022608799 · Cited by 162
Self-citationEhrlich, H. J., Gebbink, R. K., Keijer, J., et al. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38262-6 · Cited by 159
Stability of Plasminogen Activator Inhibitor 1 (PAI-1)
Lindahl, T. L., Sigurðardóttir, Ó., & Wiman, B. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646895 · Cited by 151
Distribution of plasminogen activator inhibitor (PAI-1) in tissues.
Simpson, A. J., Booth, N. A., Moore, N. R., & Bennett, B. (1991) · Journal of Clinical Pathology · doi:10.1136/jcp.44.2.139 · Cited by 151
Skurk, T., Lee, Y., & Hauner, H. (2001) · Hypertension · doi:10.1161/01.hyp.37.5.1336 · Cited by 150
Fay, W., Eitzman, D. T., Shapiro, A. D., Madison, E., & Ginsburg, D. (1994) · Blood · doi:10.1182/blood.v83.2.351.bloodjournal832351 · Cited by 148
Kates, R. E., Gauger, K., Willems, A., Kiechle, M. B., Magdolen, V., Schmitt, M., & Harbeck, N. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0798 · Cited by 147
Quax, P. H. A., van den Hoogen, C. M., Verheijen, J. H., Padró, T., Zeheb, R., GELEHRTER, T. D., van Berkel, T. J. C., Kuiper, J., & Emeis, J. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55433-8 · Cited by 143
PAI-1, fibrosis, and the elusive provisional fibrin matrix
Loskutoff, D. J., & Quigley, J. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11765 · Cited by 143
Self-citationHou, B., Eren, M., Painter, C., Covington, J. W., Dixon, J. D., Schoenhard, J. A., & Vaughan, D. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310438200 · Cited by 143
Pyke, C., Kristensen, P. K., Ralfkiaer, E. M., Eriksen, J., & Danø, K. (1991) · PubMed · Cited by 143
The c- myc -Regulated Gene mr1 Encodes Plasminogen Activator Inhibitor 1
Prendergast, G. C., Diamond, L. E., Dahl, D., & Cole, M. D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.3.1265 · Cited by 140
Morange, P., LIJNEN, H. R., Alessi, M., Kopp, F., Collen, D., & Juhan-Vague, I. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.4.1150 · Cited by 140
Deng, G. G., Curriden, S. A., Hu, G., Czekay, R., & Loskutoff, D. J. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.1133 · Cited by 139
Self-citationTissue-type plasminogen activator: a historical perspective and personal account
Collen, D., & Lijnen, H. R. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7933.2004.00645.x · Cited by 134
Huang, Y., Haraguchi, M., Lawrence, D. A., Border, W. A., Yu, L. H., & Noble, N. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18038 · Cited by 134
Inactivation of plasminogen activator inhibitor by oxidants
Lawrence, D. A., & Loskutoff, D. J. (1986) · Biochemistry · doi:10.1021/bi00369a001 · Cited by 131
Self-citationBIRGITTASUNDELL, I., Nilsson, T. K., Hallmans, G., Hellsten, G., & Dahlén, G. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90062-2 · Cited by 129
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199801000-00017 · Cited by 129
Stefansson, S., Muhammad, S., Cheng, X., Battey, F. D., Strickland, D. K., & Lawrence, D. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6358 · Cited by 127
Brown, N. J., Agirbasli, M., & Vaughan, D. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.285 · Cited by 124
Kjøller, L. (2002) · Biological Chemistry · doi:10.1515/bc.2002.002 · Cited by 122
Morange, P., Aubert, J., Peiretti, F., LIJNEN, H. R., Vague, P., Verdier, M., Négrel, R., Juhan-Vague, I., & Alessi, M. (1999) · Diabetes · doi:10.2337/diabetes.48.4.890 · Cited by 115
Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Chazaud, B., Ricoux, R., Christov, C., Plonquet, A., Gherardi, R., & Barlovatz-Meimon, G. (2002) · American Journal of Pathology · doi:10.1016/s0002-9440(10)64367-2 · Cited by 114
Inhibitors of Fibrinolysis Are Elevated in Atherosclerotic Plaque
ROBBIE, L. A., Booth, N. A., Brown, P. A., & Bennett, B. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.4.539 · Cited by 111
Impact of Adipose Tissue on Plasma Plasminogen Activator Inhibitor-1 in Dieting Obese Women
Mavri, A., Stegnar, M., Krebs, M., Sentočnik, J. T., Geiger, M., & Binder, B. R. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.6.1582 · Cited by 102
Stringer, H., van Swieten, P., Heijnen, H. F. G., Sixma, J. J., & Pannekoek, H. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.9.1452 · Cited by 100
Serine Protease Inhibitors: Novel Therapeutic Targets for Stroke?
Vivien, D., & Buisson, A. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200005000-00001 · Cited by 97
Zhu, Y., Farrehi, P. M., & Fay, W. P. (2001) · Circulation · doi:10.1161/01.cir.103.25.3105 · Cited by 94
Gils, A., & Declerck, P. J. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0764 · Cited by 93
Schäfer, K., Müller, K., Hecke, A., Mounier, E., Goebel, J., Loskutoff, D. J., & Konstantinides, S. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000097766.36623.df · Cited by 86
Self-citationYepes, M., & Lawrence, D. A. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0766 · Cited by 83
Stahl, A., & Mueller, B. M. (1997) · International Journal of Cancer · Cited by 83
Plasminogen Activator Inhibitor-1 Levels and Polymorphisms
Francis, C. W. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1401-pailap · Cited by 82
Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin
Podor, T. J., Peterson, C. B., Lawrence, D. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908079199 · Cited by 73
Offersen, B. V., Nielsen, B. S., Høyer‐Hansen, G., Rank, F. E., Hamilton-Dutoit, S. J., Overgaard, J., & Andreasen, P. A. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63547-x · Cited by 69
Fearns, C., & Loskutoff, D. J. (1997) · Europe PMC (PubMed Central) · Cited by 67
Self-citationSamad, F., Pandey, M., Bell, P. A., & Loskutoff, D. J. (2000) · Molecular Medicine · doi:10.1007/bf03402048 · Cited by 66
Self-citationOld Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration
Stefansson, S., & Lawrence, D. A. (2003) · Science Signaling · doi:10.1126/scisignal.1892003pe24 · Cited by 64
Dichtl, W., Stiko, A., Eriksson, P. O., Gonçalves, I., Calara, F. B., Banfi, C., Ares, M. P. S., Hamsten, A., & Nilsson, J. Å. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.12.3025 · Cited by 45
Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?
Konstantinides, S., Schäfer, K., & Loskutoff, D. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000047462.65341.22 · Cited by 39
Self-citationCarmassi, F., Morale, M., Ferrini, L., Dell’Omo, G., Ferdeghini, M., Pedrinelli, R., & Negri, F. D. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00240-5 · Cited by 36
Nilsson, L., Gåfvels, M. E., Musakka, L., Ensler, K., Strickland, D. K., Angelin, B., Hamsten, A., & Eriksson, P. O. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32126-x · Cited by 33
Kirchheimer, J. C., Binder, B. R., & Remold, H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.5.1518 · Cited by 33
Panahloo, A., Mohamed‐Ali, V., Andrés, C., Denver, A. E., & Yudkin, J. S. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90023-3 · Cited by 28
Release of PAI-1 by Human Preadipocytes and Adipocytes Independent of Insulin and IGF-1
Crandall, D. L., Groeling, T. M., Busler, D. E., & Antrilli, T. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4045 · Cited by 26
Tanaka, S., Koyama, H., Ichii, T., Shioi, A., Hosoi, M., Raines, E. W., & Nishizawà, Y. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000028002.60919.4d · Cited by 26
Curino, A. C., Mitola, D. J., Aaronson, H., McMahon, G. A., Raja, K., Keegan, A. D., Lawrence, D. A., & Bugge, T. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205951 · Cited by 25
Bastholm, L., Nielsen, M. H., Mey, J. D., Danø, K., Brünner, N., Høyer‐Hansen, G., Rønne, E., & Elling, F. (1994) · Biotechnic & Histochemistry · doi:10.3109/10520299409106263 · Cited by 20
Cited by
The role of saliva in tick feeding
Francischetti, I. (2009) · Frontiers in Bioscience · doi:10.2741/3363 · Cited by 581
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Therapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 388
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Yang, G., Badeanlou, L., Bielawski, J., Roberts, A. J., Hannun, Y. A., & Samad, F. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.91014.2008 · Cited by 295
Metadata
- Authors
- Dellas, C., & Loskutoff, D. J.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 04
- Pages
- 631-640
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2074672488
- Cited by
- 285
- References
- 120
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.